TALPHERA, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TALPHERA, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $475.0K | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $608.0K | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $941.0K | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $265.0K | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | $613.0K | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | $377.0K | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $818.0K | Mar 16, 2020 |
| FY2019 | Mar 31, 2018 | $343.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $740.0K | Mar 7, 2019 |
| FY2018 | Sep 30, 2017 | $1.49M | Mar 7, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.29M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($13.00M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($18.40M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $47.76M | Mar 6, 2024 |
| FY2022 | Sep 30, 2022 | $55.24M | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | $70.66M | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | ($35.10M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($40.38M) | Mar 10, 2022 |
| FY2019 | Dec 31, 2019 | ($14.42M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($12.73M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.48M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($15.25M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($16.89M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($25.30M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($35.97M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($40.96M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($54.21M) | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | ($35.73M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($38.68M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($31.96M) | Mar 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.03M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $6.72M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $5.55M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $3.34M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $4.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.02M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $4.66M | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | $13.14M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $19.41M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $21.40M | Mar 7, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.48M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $8.53M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $11.99M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.01M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $30.94M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $36.33M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $45.03M | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | $20.77M | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $16.61M | Mar 16, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.36M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($12.68M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($17.49M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($28.33M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($30.00M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($38.51M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($51.18M) | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | ($29.08M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | ($29.77M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($29.40M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 31, 2025 |
| FY2024 | Dec 31, 2023 | $100.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $364.0K | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $1.83M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.86M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $3.47M | Mar 15, 2021 |
| FY2020 | Dec 31, 2018 | $819.0K | Mar 15, 2021 |
| FY2019 | Dec 31, 2017 | $2.41M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $3.72M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $1.46M | Mar 9, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.72M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $18.24M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $20.40M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $47.49M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $77.89M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $66.30M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $91.36M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $120.53M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $75.55M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $99.99M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.68M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $10.24M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $6.29M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.67M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $113.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $122.05M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $132.77M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $116.28M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $112.06M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $105.33M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.04M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $8.00M | Mar 23, 2026 |
| FY2025 | Dec 31, 2023 | $14.11M | Mar 23, 2026 |
| FY2024 | Dec 31, 2022 | $21.81M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | ($35.89M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2020 | ($55.75M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($41.42M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | $4.25M | Mar 15, 2021 |
| FY2020 | Dec 31, 2017 | ($36.51M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2016 | ($5.34M) | Mar 16, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($471.52M) | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | ($457.23M) | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | ($444.23M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($425.83M) | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | ($473.58M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($438.49M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($398.11M) | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | ($345.02M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($297.87M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($246.36M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.89M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | $8.86M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | $5.72M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $15.28M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | $7.66M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $27.27M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $14.68M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | $87.98M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $52.90M | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $80.31M | Mar 7, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $13.80M | Mar 10, 2022 |
| FY2020 | Dec 31, 2020 | $21.88M | Mar 15, 2021 |
| FY2019 | Dec 31, 2019 | $25.15M | Mar 16, 2020 |
| FY2018 | Dec 31, 2018 | $11.99M | Mar 7, 2019 |
| FY2017 | Dec 31, 2017 | $19.10M | Mar 9, 2018 |
| FY2016 | Dec 31, 2016 | $21.55M | Mar 3, 2017 |
| FY2015 | Dec 31, 2015 | $20.92M | Mar 7, 2016 |
| FY2014 | Dec 31, 2014 | $24.91M | Mar 13, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 5 | Mar 6, 2024 |
| FY2022 | Sep 30, 2022 | 6 | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | 8 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Mar 31, 2023 |
| FY2017 | Dec 31, 2017 | 0 | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 9, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | (1) | Mar 6, 2024 |
| FY2023 | Dec 31, 2022 | 5 | Mar 6, 2024 |
| FY2022 | Sep 30, 2022 | 6 | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | 8 | Mar 31, 2023 |
| FY2022 | Dec 31, 2021 | (5) | Mar 31, 2023 |
| FY2017 | Dec 31, 2017 | 0 | Mar 9, 2018 |
| FY2017 | Sep 30, 2017 | 0 | Mar 9, 2018 |
| FY2017 | Jun 30, 2017 | 0 | Mar 9, 2018 |
| FY2017 | Mar 31, 2017 | 0 | Mar 9, 2018 |
| FY2017 | Dec 31, 2016 | 0 | Mar 9, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.33M | Mar 23, 2026 |
| FY2025 | Dec 31, 2024 | 17.03M | Mar 23, 2026 |
| FY2024 | Dec 31, 2023 | 16.95M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 8.24M | Mar 6, 2024 |
| FY2022 | Dec 31, 2021 | 6.84M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 98.81M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 79.57M | Mar 15, 2021 |
| FY2019 | Dec 31, 2018 | 78.76M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 50.90M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 45.33M | Mar 9, 2018 |